Compass says depression drug has long-lasting benefits
Compass Pathways reports positive six-month data for its psilocybin-based depression treatment, fueling market confidence and future filing plans.
Coverage (7)
- COMP360 Psilocybin Sustains Depression Benefit Through 26 Weeks HCPLive · 47d ago
- Compass Pathways Is Maintained at Buy by BTIG Moomoo · 47d ago
- Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile Business Wire · 47d ago
- Compass Pathways Shares Gain on Positive Late-Stage Trial Data for Depression Treatment Moomoo · 47d ago
- Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch Psychedelic Alpha · 47d ago
- Updated: Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing Endpoints News · 47d ago
- Compass says depression drug has long-lasting benefits STAT · 47d ago broke it first
The brief
Compass Pathways has released results from its second Phase 3 clinical trial involving the investigational drug COMP360. Data indicates that the psilocybin treatment maintained depression-related benefits for participants through a 26-week period.
Coverage from outlets including STAT, Endpoints News, and Business Wire emphasizes the durability and rapid onset of the drug's effects. Financial analysis and market reporting from Moomoo, BTIG, and Psychedelic Alpha highlight positive shifts in company stock performance and the maintenance of a buy rating for the firm.
Attention now shifts to the company's regulatory timeline. Reported plans include a year-end filing with health authorities, with the organization looking toward a potential launch in the first half of 2027.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 44d ago.
Quick answers
What is the duration of the benefits reported?
Clinical trial data confirms that benefits were sustained through 26 weeks.
When does Compass Pathways anticipate a product launch?
The company is targeting a launch in the first half of 2027.
How have analysts responded to the data?
BTIG has maintained a buy rating for Compass Pathways, and shares have gained following the announcement.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
People, places & organizations
Topics
Related trends
First person gets new experimental vaccine for Ebola
The world's first vaccine targeting the Bundibugyo ebolavirus has entered human clinical trials following the first volunteer vaccination.
Pancreatic cancer vaccine shows promise in first human trial, preventing disease in high-risk patients
A first-in-human clinical trial for a mutant KRAS vaccine shows promise in preventing pancreatic cancer among high-risk patients.
Common Digestive Drug May Help Ease Depression and Brain Fog
A common drug used to treat constipation is being linked to improved brain function and a reduction in brain fog for those with depression.
Can 2 drugs work better than 1 against Alzheimer’s? UCSF aims to find out
UCSF has begun screening patients for a novel trial testing whether a combination of two drugs is more effective against Alzheimer's than a single treatment.
There's no treatment designed for the Ebola strain ravaging DRC. But now there's hope
Clinical trials are underway to address a viral strain of Ebola currently affecting the Democratic Republic of Congo for which no specific treatment exists.
Grand Rapids oncologist says experimental pancreatic cancer drug showing promise in trials offers hope
An experimental drug targeting pancreatic cancer is showing promising survival gains in clinical trials.